Assembly Biosciences, Inc. (NASDAQ:ASMB) CEO Sells $19,941.99 in Stock

Assembly Biosciences, Inc. (NASDAQ:ASMB) CEO Jason A. Okazaki sold 1,569 shares of the company’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $12.71, for a total value of $19,941.99. Following the completion of the transaction, the chief executive officer now owns 16,423 shares in the company, valued at $208,736.33. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Assembly Biosciences Trading Up 2.7 %

Shares of NASDAQ:ASMB opened at $13.15 on Friday. Assembly Biosciences, Inc. has a 1 year low of $7.69 and a 1 year high of $20.04. The firm’s 50-day moving average is $13.23 and its two-hundred day moving average is $11.19.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. HC Wainwright restated a “neutral” rating on shares of Assembly Biosciences in a report on Monday, April 1st. StockNews.com upgraded Assembly Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, April 5th.

Hedge Funds Weigh In On Assembly Biosciences

An institutional investor recently bought a new position in Assembly Biosciences stock. Acuitas Investments LLC purchased a new position in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 265,585 shares of the biopharmaceutical company’s stock, valued at approximately $218,000. Acuitas Investments LLC owned 0.40% of Assembly Biosciences at the end of the most recent reporting period. Institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.